Renexxion
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact

​Mechanism of Action

Naronapride is an orally bioavailable, small organic molecule. It was designed to be a potent and selective serotonin 5-HT4 receptor agonist. Stimulating 5-HT4 receptors in the gut wall promotes the release of acetylcholine, which works to increase motility of the GI tract. The high 5-HT4 receptor selectivity minimizes the potential for off-target pharmacological effects. Indeed, it has been shown in animals and in humans to be safe and devoid of adverse cardiovascular effects.
Privacy Policy & Terms of Use 
​Copyright Renexxion 2016. All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact